DNDi Receives USD 25.7 million from the Bill & Melinda Gates Foundation to Develop New Medicines to treat human African trypanosomiasis (HAT) and visceral leishmaniasis (VL). The grant, to be disbursed over five years, will provide critical funding for the R&D of new drug candidates for HAT and VL. DNDi will foster the development of the drug candidates through the preclinical stages and select one lead candidate for each disease to advance into Phase I human clinical trials.

A Private Swiss Foundation grants DNDi CHF 540'000 over 2 years for Drug Candidate Evaluation for Chagas Disease and Leishmaniasis.

The French Ministry of European and Foreign Affairs grants EUR 6 million to be disbursed over 3 years to support clinical projects for VL and HAT as well as two clinical trials platforms set up in Africa.

Spain's Agencia Española de Cooperación Internacional (AECI) granted EUR 5 million to DNDi for essential R&D of drugs for neglected diseases.
The grant, spread over two years, demonstrates the commitment of the Spanish government to support research and development on neglected diseases, and will provide core initiative funding for DNDi.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), granted DNDi USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.